Trial document
DRKS00000531
Trial Description
Title
Polypharmacy as a result of multiple chronic conditions of older people: rational therapy with the new FORTA classification?
Trial Acronym
[---]*
URL of the Trial
[---]*
Brief Summary in Lay Language
Polyphramacy, overtreatment, and undertreatment with drugs are frequent in older subjects. Since there are no guidelines for the management of this problem, the newly developed FORTA (fit for the aged) classification was created to support the clinical decission making of pharmacological treatment in old age. However, the FORTA classification was never tested in clinical practice.
In the current study, the medication will be reviewed by the criteria of the new FORTA classification in a sample of geriatric in-hospital patients. Treatment will be adjusted then accordingly in one patient group (cluster I). In a second cluster of patients, pharmacological treatment is applied according to good clinical practice. Furthermore, all prevalent diseases were recorded and checked whether they are adequately treated.
The aim of the study is to estimate the impact of the application of the FORTA classification on the quality of pharmacological prescription in a sample of older in-hospital patients.
A second aim is to identify and quantify pharmacological overtreatment and undertreatment.
Brief Summary in Scientific Language
Cluster randomized study in 400 geriatric clinic patients with review of current medication based on the new FORTA classification, recording of all prevalent diseases and assessing of the need of treatment. Adjustment of the medication according to FORTA in one patient cluster, continuing the medication in the second patient cluster according to the rules of good meidcal practice.
The main outcome of the study is the extent of the effect of applying FORTA on pharmacotherapy by comparing treatments between the two custers.
A second aim is to identify over- and undertreatment of diseases and comparison of the frequencies between both clusters.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00000531
- 2010/09/15
- [---]*
- yes
- Approved
- 2010-273N-MA, Medizinische Ethik-Kommission II Medizinische Fakultät Mannheim der Universität Heidelberg
Secondary IDs
- U1111-1116-6958
Health Condition or Problem studied
- eligible for the study are patients of a geriatric unit with numerous co-morbid conditions.
Interventions/Observational Groups
- Review and adjustment of medication according to the FORTA criteria
- Continue the medication according to guidelines and Good Medical Practice
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Single blind
- patient/subject
- Active control
- Health economics
- Parallel
- N/A
- [---]*
Primary Outcome
The FORTA classification encompasses four classes of drugs. Drugs with well documented evidence for the elderly constitute the classes A and B, drugs with limited evidence constitute the class C. Drug of the class D should be avoided in the elderly.
The aim of the study is the statistical measurement of the difference in the distribution of medication at discharge according to the four classes of FORTA between the two patient groups (clusters).
Secondary Outcome
Statistically comparisone of the the two clusters regarding
Number of untreated disease
Number of diseases overtreated
Countries of Recruitment
- Germany
Locations of Recruitment
- [---]*
Recruitment
- Actual
- 2011/11/28
- 400
- Multicenter trial
- National
Inclusion Criteria
- Both, male and female
- 65 Years
- 100 Years
Additional Inclusion Criteria
informed consent given,
stable clinical condition,
no palliative condition
Exclusion Criteria
missing informed consent,
palliative clinical condition,
unstable clinical condition,
need of intensive care unit (ICU) treatment
Addresses
-
start of 1:1-Block address primary-sponsor
- Institut für klinische Pharmakologie Mannheim Universität Heidelberg
- Mr. Prof. Dr. Martin Wehling
- Maybachstraße 14
- 68169 Mannheim
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- 0621-3839631
- 0621-3839632
- martin.wehling at medma.uni-heidelberg.de
- http://www.ma.uni-heidelberg.de
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address secondary-sponsor
- Kliniken Essen Mitte Zentrum für Altersmedizin
- Mr. Dr. Helmut Frohnhofen
- Am deimelsberg 34a
- 45276 Essen
- Germany
end of 1:1-Block address secondary-sponsorstart of 1:1-Block address contact secondary-sponsor- 0201-174-23001
- 0201-174-23000
- h.frohnhofen at kliniken-essen-mitte.de
- http://www.kliniken-essen-mitte.de
end of 1:1-Block address contact secondary-sponsor -
start of 1:1-Block address scientific-contact
- Institut für klinische Pharmakologie Universität Heidelberg-Mannheim
- Mr. Prof. Dr. med. Martin Wehling
- Maybachstraße 14
- 68169 Mannheim
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 0621-3839631
- 0621-3839632
- martin.wehling at medma.uni-heidelberg.de
- http://www.ma.uni-heidelberg.de
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Kliniken Essen Mitte Zentrum für Altersmedizin
- Mr. Dr. med. Helmut Frohnhofen
- Am Deimelsberg 34a
- 45276 Essen
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 0201-17423001
- 0201-17423000
- h.frohnhofn at kliniken-essen-mitte.de
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Institut für klinische Pharmakologie Mannheim Universität Heidelberg
- Mr. Prof. dr. Martin Wehling
- Maybachstraße 14
- 68169 Mannheim
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- 0621-3839631
- 0621-3839632
- martin.wehling at medma.uni-heidelberg.de
- http://www.ma.uni-heidelberg.de
end of 1:1-Block address contact materialSupport -
start of 1:1-Block address otherSupport
- Deutsche Forschungsgemeinschaft
- Kennedyallee 40
- 53175 Bonn
- Germany
end of 1:1-Block address otherSupportstart of 1:1-Block address contact otherSupport- [---]*
- [---]*
- [---]*
- http://www.dfg.de
end of 1:1-Block address contact otherSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- Frohnhofen H, Michalek C, Wehling M. Assessment of drug treatment in geriatrics with the new FORTA criteria Dtsch Med Wschr 2011; 136(27): 1417-1421